Methylation status of Oestrogen, Progesterone, Human Epidermal Growth
Research type
Research Study
Full title
Methylation status of Oestrogen, Progesterone, Human Epidermal Growth Factor and expression of PDL-1 in Triple Negative Breast Cancer (TNBC)
IRAS ID
239241
Contact name
Alexander Makanga
Contact email
Sponsor organisation
BCUHB
Duration of Study in the UK
0 years, 5 months, 30 days
Research summary
Breast cancer remains one of the leading causes of death in women with other 400,000 estimated deaths every year. Aside the loss of life, breast cancer presents a huge public health burden as well as economic burdens for the global populations. Triple-negative breast cancer (TNBC) is considered the most aggressive form of breast cancer with low survival rates. Currently TNBC are identified by their unique lack of expression of three antibodies using immunohistochemistry ie estrogen receptor (ER), progesterone receptor (PR) and the human epidermal growth factor 2 (HER-2). Since current treatment/management guidelines are tailored towards the expressions of these three antibodies, treatment for TNBC presents a huge challenge. It is therefore, essential to identify and develop an alternative pathway for treatment and management of this subgroup. The methylation status of ER, PR, HER-2 and DNA repair genes of breast cancer patients may provide more information about the patient outcome. This study, therefore, seeks to identify the methylation status of patients and investigate their relationship with outcome. Furthermore, this study also seeks to examine the expression of PDL- 1 in TNBC.
REC name
Wales REC 5
REC reference
18/WA/0055
Date of REC Opinion
10 Apr 2018
REC opinion
Further Information Favourable Opinion